Jan Marek Slominski

Jan Marek Slominski

Auto-generated profile, based on publicly available information

Jan Marek Slominski

Department of Pulmonology, Medical University of Gdansk, Gdansk, Poland

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1984 in JACC
Verified
Journal Article
Closed access
FFFetnat M. Fouad
Fetnat M. Fouad
JSJ. Marek Slominski
J. Marek Slominski
RTRobert C. Tarazi
Robert C. Tarazi

25 February 2014 in Advances in Respiratory Medicine
Verified
Journal Article
Open access
DWDariusz Wiśniewski
Dariusz Wiśniewski
MPMaria Porzezińska
Maria Porzezińska
MGMarta Gruchała-Niedoszytko
Marta Gruchała-Niedoszytko
MNMarek Niedoszytko
Marek Niedoszytko
JSJan Słomiński
Jan Słomiński
EJEwa Jassem
Ewa Jassem
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. Systematic treatment of COPD decreases symptoms and reduces the frequency of exacerbations and hospitalisations because of the disease. It is estimated that only 50% of patients use prescribed drugs systematically. The aim of this study was to identify the factors which can influence adherence to treatment of the patients who were treated due to exacerbation of COPD. Material and Methods: A questionnaire probe was conducted on 49 patients hospitalised at the Regional Lung and Tuberculosis Hospital in Olsztyn, Poland due to COPD exacerbation. The assessed variables were: quality of life and adherence to treatment 30 days after discharge from hospital in relationship with demographic factors, social status, disease and hospitalisation course, and relief after systematic treatment. Results: Most of the patients assessed their health condition as poor and the disease as limiting their everyday social and occupational activity. 30 days after discharge from hospital the adherence rate to therapy was only 67%. There was an association between systematic treatment and the rate of exacerbations (p = 0.045) and hospitalisations (p = 0.005) but also clinical benefit after long-term treatment (p = 0.023). There were no associations between adherence to treatment and sex, place of residence, education or occupation. Conclusions: Lack of systematic treatment is the main risk factor for COPD exacerbations and hospitalisation rate. A subjective sense of relief after drugs is a factor improving patients’ compliance.

1 January 2002 in Lung Cancer
Verified
Journal Article
Closed access
JJJacek Jassem
Jacek Jassem
MKMaciej Krzakowski
Maciej Krzakowski
KRKazimierz Roszkowski
Kazimierz Roszkowski
RRRodryg Ramlau
Rodryg Ramlau
JSJan Marek Słomiński
Jan Marek Słomiński
KMKrzysztof Miracki
Krzysztof Miracki

1 January 2015
Verified
Book Chapter
Closed access
PDF file
MTMarlena Typiak
Marlena Typiak
KRK. Rębała
K. Rębała
MDM. Dudziak
M. Dudziak
JSJ. M. Słomiński
J. M. Słomiński
ADAnna Dubaniewicz
Anna Dubaniewicz

12 January 2015 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
AGAleksandra Maria Górska
Aleksandra Maria Górska
MNMarek Niedoszytko
Marek Niedoszytko
MLMagdalena Lange
Magdalena Lange
MCMarta Joanna Chełmińska
Marta Joanna Chełmińska
Bogusław NedoszytkoBogusław Nedoszytko
Bogusław Nedoszytko
EJEwa Jassem
Ewa Jassem
Symptoms resulting from the activation and release of mediators from the mast cells are observed in about 30% of the patients with mastocytosis. The aim of the study was to assess the prevalence of anaphylactic reactions and to identify the risk factors for anaphylaxis in patients with mastocytosis depending on the type of the disease. Furthermore, we analyzed a response to treatment of mediator-related symptoms in this patient group. The study group included 152 adult patients with mastocytosis. The diagnostic workup included a histopathological examination, flow cytometry, KIT mutation analysis, and measurement of tryptase levels. The diagnosis of allergy was confirmed by the skin prick test and serum immunoglobulin E levels. The prevalence of anaphylactic reactions in the study group was 50% and was higher in patients with systemic mastocytosis (P = 0.007), specifically in its indolent variant (P = 0.026), than in patients with cutaneous mastocytosis. The most frequent triggers of anaphylaxis were food (29%), insect stings (22%), and drugs (15%). Tryptase levels were higher in patients with a history of anaphylaxis (P = 0.029) as well as in those with symptoms provoked by physical factors (P = 0.002). Such symptoms were reported in 112 patients (74%) and were more common in patients with systemic mastocytosis compared with those with cutaneous mastocytosis (P = 0.026). The treatment was ineffective in 8 patients (10.5%) and resulted only in partial remission in 14 patients (18.4%). The study showed a significant incidence of symptoms related to physical factors in patients with mastocytosis and anaphylaxis in history. Risk factors for anaphylaxis included increased serum tryptase levels and indolent variant of systemic mastocytosis. Standard pharmacological treatment was ineffective in 10% of the patients, who may require biological treatment.

29 June 2012
Verified
Book Chapter
Closed access
PDF file
ADAnna Dubaniewicz
Anna Dubaniewicz
AZA. Zimmermann
A. Zimmermann
MSM. Smigielska
M. Smigielska
MDM. Dubaniewicz-Wybieralska
M. Dubaniewicz-Wybieralska
GMG. Moszkowska
G. Moszkowska
PDP. Deeg
P. Deeg